Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial

OBJECTIVE: Yohimbine pharmacokinetics were determined after oral administration of a single oral dose of yohimbine 5 mg and a microdose of yohimbine 50 µg in relation to different cytochrome P450 (CYP) 2D6 genotypes. The CYP2D6 inhibitor paroxetine was used to investigate the influence on yohimbine...

Descripción completa

Detalles Bibliográficos
Autores principales: Vay, Manuela, Meyer, Marleen Julia, Blank, Antje, Skopp, Gisela, Rose, Peter, Tzvetkov, Mladen Vassilev, Mikus, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329762/
https://www.ncbi.nlm.nih.gov/pubmed/32060866
http://dx.doi.org/10.1007/s40262-020-00862-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329762/
https://www.ncbi.nlm.nih.gov/pubmed/32060866
http://dx.doi.org/10.1007/s40262-020-00862-6

Ejemplares similares